Nodulocystic acne — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGeneral dermatology & dermatology in primary health careNodulocystic acneSCE Dermatology

A 17-year-old boy has painful nodules, cysts and early scarring on the cheeks and upper back despite 4 months of topical adapalene-benzoyl peroxide and oral doxycycline. He is socially withdrawn because of the acne. What is the most appropriate next step. What is the most appropriate treatment?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Refer for consideration of oral isotretinoin

The correct answer is E, refer for consideration of oral isotretinoin. This boy has nodulocystic acne with early scarring and psychosocial impact, and he has already failed an adequate 4 month course of a first-line combination (topical retinoid plus benzoyl peroxide with an oral tetracycline). NICE guidance recommends considering oral isotretinoin, via referral to a dermatologist-led team, for people with severe acne resistant to adequate courses of systemic antibiotics and topical therapy, particularly where scarring risk is present. Isotretinoin is not initiated in primary care because of teratogenicity, monitoring requirements and prescribing restrictions under MHRA safety measures, so referral is the correct next step rather than direct prescribing. Why the other options are wrong: D. Continue the same regimen for another year: prolonging an already failed antibiotic-containing regimen risks antimicrobial resistance, does not address ongoing scarring, and contradicts guidance to escalate after inadequate response. A. Add topical fusidic acid to each nodule: topical antibiotics are not indicated for nodulocystic disease, add resistance risk, and have no role as monotherapy escalation for scarring acne. C. Start oral prednisolone as monotherapy: systemic steroids are reserved for acne fulminans or as short adjuncts before isotretinoin under specialist care, not as standalone treatment for standard nodulocystic acne. B. Use topical hydrocortisone on inflamed papules: a mild topical steroid has no evidence base in acne management and does not treat the underlying follicular occlusion, inflammation or scarring risk. Key point: severe nodulocystic acne with scarring that has failed adequate topical plus oral antibiotic therapy should be referred for dermatology-led consideration of oral isotretinoin, not managed further in primary care.

Reference: NICE Guideline NG198, Acne vulgaris: management (2021, updated), section 1.5.18 on oral isotretinoin treatment, https://www.nice.org.uk/guidance/ng198